Sam Brusco, Associate Editor07.19.23
Onkos Surgical, a company focused on musculoskeletal oncology and complex orthopedic procedures, has launched its JTS extendible prosthesis, a novel growing implant for pediatric patients with bone cancer. The company also unveiled its new manufacturing and R&D innovation center at its Parsippany, N.J. headquarters.
Onkos’ JTS extendible prosthesis uses magnetic technology to expand non-invasively, in order to accommodate patients’ natural growth curve and preserve lower limb length equality for young patients with bone loss due to cancer.
Patrick Treacy, Onkos founder and CEO told the press, "This is a transformative time for our company, which was founded on serving this group of surgeons treating complex orthopedic procedures and the patients they care for. Pediatric sarcoma patients, who are candidates for the JTS growing prosthesis, often have complex treatment cycles in which we need to deliver precision designs in a very specific treatment window. Our investment in manufacturing innovation and design expertise will make a big difference in the future for these surgeons, patients, and families and we couldn't be more proud to serve their needs."
"This milestone reflects an exciting evolution for Onkos as the company accelerates our investments to serve the pediatric musculoskeletal oncology space and broaden our Precision Orthopaedics portfolio. The new manufacturing facility and innovation center will enable a more agile production environment and provide a world-class experience for our customers. Everything about the design of the facility is geared toward increasing speed, capacity and ownership of the supply chain to optimize our ability to deliver personalized devices," added Gary Thomas, Onkos VP of manufacturing.
Almost a year to the date, the U.S. Food and Drug Administration awarded Onkos 510(k) clearance for its My3D personalized pelvic reconstruction system.
Onkos’ JTS extendible prosthesis uses magnetic technology to expand non-invasively, in order to accommodate patients’ natural growth curve and preserve lower limb length equality for young patients with bone loss due to cancer.
Patrick Treacy, Onkos founder and CEO told the press, "This is a transformative time for our company, which was founded on serving this group of surgeons treating complex orthopedic procedures and the patients they care for. Pediatric sarcoma patients, who are candidates for the JTS growing prosthesis, often have complex treatment cycles in which we need to deliver precision designs in a very specific treatment window. Our investment in manufacturing innovation and design expertise will make a big difference in the future for these surgeons, patients, and families and we couldn't be more proud to serve their needs."
"This milestone reflects an exciting evolution for Onkos as the company accelerates our investments to serve the pediatric musculoskeletal oncology space and broaden our Precision Orthopaedics portfolio. The new manufacturing facility and innovation center will enable a more agile production environment and provide a world-class experience for our customers. Everything about the design of the facility is geared toward increasing speed, capacity and ownership of the supply chain to optimize our ability to deliver personalized devices," added Gary Thomas, Onkos VP of manufacturing.
Almost a year to the date, the U.S. Food and Drug Administration awarded Onkos 510(k) clearance for its My3D personalized pelvic reconstruction system.